Brigatinib 13C6
| Product Name | Brigatinib 13C6 |
|---|---|
| Alternate Names | Brigatinib Stable Isotopes, Stable Isotopes of Brigatinib |
| CAT No. | CS-EK-02077 |
| CAS No. | 1197953-54-0 unlabeled |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | Not Available |
| Mol. For. | Not Available |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Brigatinib |
| Therapeutic | Anti-Cancer / Oncology |
| Canonical Smiles | CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC |
| InchIKey | AILRADAXUVEEIR-UHFFFAOYSA-N |
| Inchl | InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34) |
| IUPAC | 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
[13C6]-Brigatinib is a stable isotope-labeled version of Brigatinib, a kinase inhibitor used in the treatment of non-small cell lung cancer. This labeled version has six carbon-13 atoms, which can be detected in mass spectrometry experiments to track the drug's distribution and metabolism in the body.
Brigatinib works by inhibiting the activity of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), which are proteins involved in promoting cancer cell growth. It has shown promising results in clinical trials, including the ability to cross the blood-brain barrier and treat brain metastases.
The chemical structure of [13C6]-Brigatinib is similar to that of Brigatinib, with the addition of six carbon-13 atoms in the molecule. This labeling does not affect the drug's therapeutic properties, but it allows for more precise analysis of its pharmacokinetics and pharmacodynamics in vivo.
[13C6]-Brigatinib is typically used in preclinical studies to study drug distribution, metabolism, and pharmacokinetics in animal models. It can also be used in clinical studies to track drug metabolism and bioavailability in humans. Its use can help researchers better understand how the drug is processed by the body and how it interacts with target proteins, which can inform dosing strategies and improve treatment outcomes.
Get an Instant Quote
Related Compounds
Brigatinib D3 | Brigatinib D11 | Brigatinib-d6 |